Combination therapy with antibiotics and Anthrax Immune Globulin Intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax

Srinivas Kammanadiminti, Ravi Kumar Patnaikuni, Jason Comer, Gabriel Meister, Chris Sinclair, Shantha Kodihalli

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: We have evaluated the therapeutic efficacy of AIGIV when given in combination with levofloxacin and the effective window of treatment to assess the added benefit provided by AIGIV over standard antibiotic treatment alone in a New Zealand white rabbit model of inhalational anthrax. Methods: Rabbits were exposed to lethal dose of aerosolized spores of Bacillus anthracis (Ames strain) and treated intravenously with either placebo, (normal immune globulin intravenous, IGIV) or 15 U/kg of AIGIV, along with oral levofloxacin treatment at various time points (30-96 hours) after anthrax exposure. Results: The majority of treated animals (>88%) survived in both treatment groups when treatment was initiated within 60 hours of post-exposure. However, reduced survival of 55%, 33% and 25% was observed for placebo + levofloxacin group when the treatment was initiated at 72, 84 and 96 hours post-exposure, respectively. Conversely, a survival rate of 65%, 40% and 71% was observed in the AIGIV + levofloxacin treated groups at these time points. Conclusions: The combination of AIGIV with antibiotics provided an improvement in survival compared to levofloxacin treatment alone when treatment was delayed up to 96 hours post-anthrax exposure. Additionally, AIGIV treatment when given as an adjunct therapy at any of the time points tested did not interfere with the efficacy of levofloxacin.

Original languageEnglish (US)
Article numbere106393
JournalPloS one
Volume9
Issue number9
DOIs
StatePublished - Sep 16 2014
Externally publishedYes

Fingerprint

Anthrax
anthrax
Intravenous Immunoglobulins
Levofloxacin
immunoglobulins
antibiotics
rabbits
Anti-Bacterial Agents
Rabbits
therapeutics
Therapeutics
placebos
Bacilli
home furnishings
Anthrax Immune Globulin Intravenous
Bacillus anthracis
Placebos
New Zealand White rabbit
lethal dose
Animals

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Combination therapy with antibiotics and Anthrax Immune Globulin Intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax. / Kammanadiminti, Srinivas; Patnaikuni, Ravi Kumar; Comer, Jason; Meister, Gabriel; Sinclair, Chris; Kodihalli, Shantha.

In: PloS one, Vol. 9, No. 9, e106393, 16.09.2014.

Research output: Contribution to journalArticle

Kammanadiminti, Srinivas ; Patnaikuni, Ravi Kumar ; Comer, Jason ; Meister, Gabriel ; Sinclair, Chris ; Kodihalli, Shantha. / Combination therapy with antibiotics and Anthrax Immune Globulin Intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax. In: PloS one. 2014 ; Vol. 9, No. 9.
@article{ecc23e9d78484832bba2b25c6759fcb2,
title = "Combination therapy with antibiotics and Anthrax Immune Globulin Intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax",
abstract = "Background: We have evaluated the therapeutic efficacy of AIGIV when given in combination with levofloxacin and the effective window of treatment to assess the added benefit provided by AIGIV over standard antibiotic treatment alone in a New Zealand white rabbit model of inhalational anthrax. Methods: Rabbits were exposed to lethal dose of aerosolized spores of Bacillus anthracis (Ames strain) and treated intravenously with either placebo, (normal immune globulin intravenous, IGIV) or 15 U/kg of AIGIV, along with oral levofloxacin treatment at various time points (30-96 hours) after anthrax exposure. Results: The majority of treated animals (>88{\%}) survived in both treatment groups when treatment was initiated within 60 hours of post-exposure. However, reduced survival of 55{\%}, 33{\%} and 25{\%} was observed for placebo + levofloxacin group when the treatment was initiated at 72, 84 and 96 hours post-exposure, respectively. Conversely, a survival rate of 65{\%}, 40{\%} and 71{\%} was observed in the AIGIV + levofloxacin treated groups at these time points. Conclusions: The combination of AIGIV with antibiotics provided an improvement in survival compared to levofloxacin treatment alone when treatment was delayed up to 96 hours post-anthrax exposure. Additionally, AIGIV treatment when given as an adjunct therapy at any of the time points tested did not interfere with the efficacy of levofloxacin.",
author = "Srinivas Kammanadiminti and Patnaikuni, {Ravi Kumar} and Jason Comer and Gabriel Meister and Chris Sinclair and Shantha Kodihalli",
year = "2014",
month = "9",
day = "16",
doi = "10.1371/journal.pone.0106393",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Combination therapy with antibiotics and Anthrax Immune Globulin Intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax

AU - Kammanadiminti, Srinivas

AU - Patnaikuni, Ravi Kumar

AU - Comer, Jason

AU - Meister, Gabriel

AU - Sinclair, Chris

AU - Kodihalli, Shantha

PY - 2014/9/16

Y1 - 2014/9/16

N2 - Background: We have evaluated the therapeutic efficacy of AIGIV when given in combination with levofloxacin and the effective window of treatment to assess the added benefit provided by AIGIV over standard antibiotic treatment alone in a New Zealand white rabbit model of inhalational anthrax. Methods: Rabbits were exposed to lethal dose of aerosolized spores of Bacillus anthracis (Ames strain) and treated intravenously with either placebo, (normal immune globulin intravenous, IGIV) or 15 U/kg of AIGIV, along with oral levofloxacin treatment at various time points (30-96 hours) after anthrax exposure. Results: The majority of treated animals (>88%) survived in both treatment groups when treatment was initiated within 60 hours of post-exposure. However, reduced survival of 55%, 33% and 25% was observed for placebo + levofloxacin group when the treatment was initiated at 72, 84 and 96 hours post-exposure, respectively. Conversely, a survival rate of 65%, 40% and 71% was observed in the AIGIV + levofloxacin treated groups at these time points. Conclusions: The combination of AIGIV with antibiotics provided an improvement in survival compared to levofloxacin treatment alone when treatment was delayed up to 96 hours post-anthrax exposure. Additionally, AIGIV treatment when given as an adjunct therapy at any of the time points tested did not interfere with the efficacy of levofloxacin.

AB - Background: We have evaluated the therapeutic efficacy of AIGIV when given in combination with levofloxacin and the effective window of treatment to assess the added benefit provided by AIGIV over standard antibiotic treatment alone in a New Zealand white rabbit model of inhalational anthrax. Methods: Rabbits were exposed to lethal dose of aerosolized spores of Bacillus anthracis (Ames strain) and treated intravenously with either placebo, (normal immune globulin intravenous, IGIV) or 15 U/kg of AIGIV, along with oral levofloxacin treatment at various time points (30-96 hours) after anthrax exposure. Results: The majority of treated animals (>88%) survived in both treatment groups when treatment was initiated within 60 hours of post-exposure. However, reduced survival of 55%, 33% and 25% was observed for placebo + levofloxacin group when the treatment was initiated at 72, 84 and 96 hours post-exposure, respectively. Conversely, a survival rate of 65%, 40% and 71% was observed in the AIGIV + levofloxacin treated groups at these time points. Conclusions: The combination of AIGIV with antibiotics provided an improvement in survival compared to levofloxacin treatment alone when treatment was delayed up to 96 hours post-anthrax exposure. Additionally, AIGIV treatment when given as an adjunct therapy at any of the time points tested did not interfere with the efficacy of levofloxacin.

UR - http://www.scopus.com/inward/record.url?scp=84907192018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907192018&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0106393

DO - 10.1371/journal.pone.0106393

M3 - Article

C2 - 25226075

AN - SCOPUS:84907192018

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e106393

ER -